Unknown

Dataset Information

0

?-casein nanovehicles for oral delivery of chemotherapeutic Drug combinations overcoming P-glycoprotein-mediated multidrug resistance in human gastric cancer cells.

ABSTRACT: Multidrug resistance (MDR) is a primary obstacle to curative cancer therapy. We have previously demonstrated that ?-casein (?-CN) micelles (?-CM) can serve as nanovehicles for oral delivery and target-activated release of hydrophobic drugs in the stomach. Herein we introduce a novel nanosystem based on ?-CM, to orally deliver a synergistic combination of a chemotherapeutic drug (Paclitaxel) and a P-glycoprotein-specific transport inhibitor (Tariquidar) individually encapsulated within ?-CM, for overcoming MDR in gastric cancer. Light microscopy, dynamic light scattering and zeta potential analyses revealed solubilization of these drugs by ?-CN, suppressing drug crystallization. Spectrophotometry demonstrated high loading capacity and good encapsulation efficiency, whereas spectrofluorometry revealed high affinity of these drugs to ?-CN. In vitro cytotoxicity assays exhibited remarkable synergistic efficacy against human MDR gastric carcinoma cells with P-glycoprotein overexpression. Oral delivery of ?-CN - based nanovehicles carrying synergistic drug combinations to the stomach constitutes a novel efficacious therapeutic system that may overcome MDR in gastric cancer.

SUBMITTER: Bar-Zeev M 

PROVIDER: S-EPMC5029629 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

β-casein nanovehicles for oral delivery of chemotherapeutic Drug combinations overcoming P-glycoprotein-mediated multidrug resistance in human gastric cancer cells.

Bar-Zeev Maya M   Assaraf Yehuda G YG   Livney Yoav D YD  

Oncotarget 20160401 17

Multidrug resistance (MDR) is a primary obstacle to curative cancer therapy. We have previously demonstrated that β-casein (β-CN) micelles (β-CM) can serve as nanovehicles for oral delivery and target-activated release of hydrophobic drugs in the stomach. Herein we introduce a novel nanosystem based on β-CM, to orally deliver a synergistic combination of a chemotherapeutic drug (Paclitaxel) and a P-glycoprotein-specific transport inhibitor (Tariquidar) individually encapsulated within β-CM, for  ...[more]

Similar Datasets

Unknown Multidomain drug delivery systems of β-casein micelles for the local oral co-administration of antiretroviral combinations.
| S-EPMC9749415 | biostudies-literature
Unknown Exploring new Horizons in overcoming P-glycoprotein-mediated multidrug-resistant breast cancer via nanoscale drug delivery platforms.
| S-EPMC8663938 | biostudies-literature
Unknown Inorganic Kernel-Reconstituted Lipoprotein Biomimetic Nanovehicles Enable Efficient Targeting "Trojan Horse" Delivery of STAT3-Decoy Oligonucleotide for Overcoming TRAIL Resistance.
| S-EPMC5695144 | biostudies-literature
Unknown Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells.
| S-EPMC5772368 | biostudies-literature
Unknown Overcoming multidrug-resistance in vitro and in vivo using the novel P-glycoprotein inhibitor 1416.
| S-EPMC3497725 | biostudies-literature
Unknown Overcoming P-Glycoprotein-Mediated Multidrug Resistance in Colorectal Cancer: Potential Reversal Agents among Herbal Medicines.
| S-EPMC6109522 | biostudies-other
Unknown Co-delivery nanoparticles with characteristics of intracellular precision release drugs for overcoming multidrug resistance.
| S-EPMC5360411 | biostudies-literature
Transcriptomics Overcoming ABCB1 mediated multidrug resistance in castration resistant prostate cancer
2024-08-08 | GSE271075 | GEO
Unknown Predicting chemotherapeutic drug combinations through gene network profiling.
| S-EPMC4726371 | biostudies-literature
Unknown Branebrutinib (BMS-986195), a Bruton's Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents.
| S-EPMC8326665 | biostudies-literature